US20090169484A1 - Iron-salen complex - Google Patents

Iron-salen complex Download PDF

Info

Publication number
US20090169484A1
US20090169484A1 US12/146,624 US14662408A US2009169484A1 US 20090169484 A1 US20090169484 A1 US 20090169484A1 US 14662408 A US14662408 A US 14662408A US 2009169484 A1 US2009169484 A1 US 2009169484A1
Authority
US
United States
Prior art keywords
amino acids
iron
hydroxyl
substituent
nhr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/146,624
Other languages
English (en)
Inventor
Haruki Eguchi
Yoshihiro Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IHI Corp
Original Assignee
IHI Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IHI Corp filed Critical IHI Corp
Assigned to IHI CORPORATION, YOSHIHIRO ISHIKAWA reassignment IHI CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EGUCHI, HARUKI, ISHIKAWA, YOSHIHIRO
Publication of US20090169484A1 publication Critical patent/US20090169484A1/en
Priority to US14/990,981 priority Critical patent/US10034941B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Definitions

  • the present invention relates to iron-salen complexes.
  • RNAi RNA interference
  • dsRNA double-stranded RNA
  • Dicer short interfering RNA
  • RISC RNA-induced silencing complexes
  • siRNA Because long dsRNA cannot be introduced without modification into mammalian cells, 21 bp chemically synthesized double-stranded siRNA is used. Synthetic double-stranded siRNA has been exploited for gene functional analysis and the screening of target genes because there is no need for the preparations and time required to prepare knock out mice with homologous recombinants, and knock down can be readily brought about by the targeted mRNA degradation using cultured cells or animal models.
  • the above compounds would be administered to the living body to reach the affected site and bring about pharmacological effects in the local affected site, leading to therapeutic efficacy, but without reaching and treating unaffected tissue (that is, normal tissue). How to effectively guide the drug to the affected site is thus critical in terms of treatment strategy. Techniques for thus guiding the drug to the affected site are referred to as drug delivery, and have become the subject of much recent research and development. This drug delivery has at least two advantages. One is that a sufficiently high concentration of the drug is obtained in the affected tissue. Pharmacological effects will not show up unless the drug concentration is at a certain level in the affected area, and no therapeutic effects can be anticipated at lower concentrations. The second is that the drug is guided only to the affected tissue and not unnecessarily to normal tissue. This can suppress adverse drug reactions.
  • anti-tumor agents inhibit the growth of cancer cells that activate mitosis, they also end up inhibiting cell growth in normal mitosis-activating tissue, such as bone marrow, hair roots, and gastrointestinal mucosa.
  • patients given anti-tumor agents thus suffer from adverse drug reactions such as anemia, hair loss, and vomiting.
  • adverse drug reactions impose a major burden on patients, a problem is that doses must be limited, preventing the pharmacological effects of the anti-tumor agents from being fully exploited. Additionally, in the worst cases, patients are at risk of dying from the adverse drug reactions. There is thus a need to be able to achieve effective therapy while suppressing adverse drug reactions by guiding anti-tumor agents to cancer cells by means of drug delivery to allow the agents to be concentrated in cancer tissues and bring about the intended pharmacological effects.
  • erectile dysfunction may also be contemplated in addition to anti-tumor agents.
  • drugs for the treatment of erectile dysfunction have interacted with nitrates, leading to serious systemic hypotension and death, a problem which occurs particularly in middle-aged or older men with heart disease. That is because drugs for the treatment of erectile dysfunction are not necessarily limited to the affected area, and affect the systemic vasculature, increasing the vasodilating action of nitrates.
  • Drug delivery may therefore also allow drugs for the treatment of erectile dysfunction to be guided to and concentrated in the affected area to bring about the intended pharmacological effect, thereby suppressing adverse drug reactions resulting from interactions with nitrates.
  • an object of the invention is to provide a drug delivery system that would be easy to use for practical purposes and that would allow conventional technical drawbacks to be overcome.
  • the present invention provides iron-salen complexes represented by any of the following Formulas (I) to (V).
  • R 2 comprises a plurality of bound nucleic acids consisting of adenine, guanine, thymine, cytosine, or uracil
  • R 1 is —Cl or —NHR 1 (where R 1 is a substituent with a hydroxyl)
  • R 2 is —H, —NH 2 , or —NHR 1 (where R 1 is a substituent with a hydroxyl)
  • the iron-salen complexes of the invention have a specific structure represented by the above Formulas (I) to (IV), resulting in better water solubility and magnetic properties.
  • the binding of substituents with an abundance of hydrogen bonds at both ends results in better water solubility and magnetic properties.
  • the iron-salen complexes of the invention are magnetic, and can thus provide magnetic drugs binding certain compounds.
  • the invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as was done in the past.
  • An AC magnetic field can be applied to the drug to increase the temperature and destroy cancer cells.
  • FIG. 1 is a block diagram schematically illustrating a test system for demonstrating the whereabouts of the drug in a magnetic field
  • FIG. 2 is a characteristics chart showing the results for cell count based on changes in drug concentration in a magnetic field
  • FIG. 3 is a perspective view showing another embodiment of the delivery device of the invention.
  • FIG. 4 is a graph of MRI results (T1 enhanced signals) for mouse kidney
  • FIG. 5 shows the result of effect of the salen complexes on melanoma growth in mice
  • FIG. 6 shows the result of melanoma extension
  • FIG. 7 shows the result of histological examination
  • FIG. 8 is a graph of the increase in temperature when an AC magnetic field is applied to the drug.
  • iron-salen complexes of the invention are represented by any of the following Formulas (I) to (V).
  • R 2 comprises a plurality of bound nucleic acids consisting of adenine, guanine, thymine, cytosine, or uracil
  • R 1 is —Cl or —NHR 1 (where R 1 is a substituent with a hydroxyl)
  • R 2 is —H, —NH 2 , or —NHR 1 (where R 1 is a substituent with a hydroxyl)
  • the charge transfer of R 1 is preferably less than 0.5 electrons (e).
  • R 1 is preferably a substituent which is the result of a hydrogen leaving any of the compounds of the following Formulas (1) to (27).
  • Taxol (paclitaxel)
  • the drugs of the invention are composed of the above iron-salen complexes.
  • a magnetic filed can be applied to the individual to guide the drug to the target tissue or affected area.
  • means for generating magnetism in the tissue or affected site of the individual can be employed to guide the drug to the tissue or affected site.
  • means for generating magnetism can be disposed in a pathway such as a blood vessel supplying the bodily fluids of the individual to the tissue or affected site of the individual, so as to guide the drug to the tissue or affected site downstream.
  • an AC magnetic filed can be applied to the drug, increasing the temperature around the cancer cells to a temperature resulting in the destruction of the cancer cells and destroying only the cancer cells.
  • the drugs of the invention can be used in drug delivery systems by which drugs administered into the body are guided by the magnetism of the drugs to a target affected area, where means are disposed for generating a magnetic field at the surface, tissue, or affected site of the individual.
  • the drugs of the invention can also be used in drug delivery systems by which drugs administered into the body are guided by the magnetism of the drugs to a target affected site, where the system is equipped with means for generating a magnetic field in the individual and means for guiding the magnetic field to the target tissue or affected site of the individual.
  • the means for generating the magnetic field is preferably designed so that the target tissue or affected site is located between a pair of magnets, allowing flux to be concentrated in the tissue or affected site.
  • the target tissue or affected site is preferably identified by MRI or CT.
  • the drugs of the invention can be used in magnetic sensors, where the magnetism or light emission of drugs administered into the body is detected to sense the pharmacokinetics of the drug.
  • the magnetism of the drugs is preferably detected by magnetic resonance induction or light emission.
  • an electromagnetic field can be applied to the drug which has been introduced into cancer tissue so as to locally elevate the temperature and selectively destroy the cancer cells.
  • iron-salen complexes of the invention will allow one drug to be used in functional diagnosis, MRI diagnostic devices, chemotherapy, biothermia, and magnetic induction drug delivery systems.
  • molecular models of drugs can be established, it can be determined whether the molecular models are magnetic based on the mathematically calculated spin charge density for the molecular models, and drugs can be designed based on molecular models that have been determined to be magnetic.
  • This method for designing drugs allows drugs to be designed by mathematical calculations such that the exchange of electrons in compounds (R 1 ) bound at both ends is less than 0.5 electrons (e).
  • This method for designing drugs allows the magnetic intensity of molecular models to be determined based on the spin charge density distribution.
  • An iron-salen complex was synthesized in the following manner.
  • An iron-salen complex was synthesized in the following manner.
  • An iron-salen complex was synthesized in the following manner.
  • the electron transfer of the compounds of Formulas (I) to (IV) and the compounds bonded to them can be determined by first principles calculation.
  • a system for computer simulation was equipped with well-known hardware as the computer, that is, memory, a computing device equipped with computing circuitry such as a CPU, and display means for the output of the computed results.
  • the memory included data specifying existing organic compound or three-dimensional structures, and software programs for performing computer simulation.
  • the software was capable of adding, modifying, and deleting compound side chains, cross linking certain side chains, calculating areas of high spin charge density, and determining the spin charge density for structures as a whole.
  • a commercially available program (Dmol3, by Accelrys) can be used, for example.
  • the user inputs the position where the side chains are to be added to a compound or selects one in which the side chains are modified or deleted, and uses a memory back up program to designate on the computer the location where cross linking should be formed.
  • the computer receives the input values to calculate the spin charge density, and outputs the results on the display screen.
  • the user can also add structural data on existing compounds to the computer system to obtain the spin charge density of existing compounds.
  • the charge transfer bonding to iron-salen complexes (Chemical Formula (I)) and the R 1 moiety can be determined by integrating the previously determined upward and downward spin charge density in three-dimensional space.
  • Table 1 shows the charge transfer binding to iron-salen complexes (Chemical Formula (I)) and to the R 1 moiety. A minus sign indicates an increase of electrons. A plus sign indicates a decrease of electrons.
  • Culture medium was sprinkled with iron-salen complex powder of the above formulas in amounts allowing magnetic attraction to be visibly observed at a rat L6 cell confluence of 30%, and the state of the medium was photographed after 48 hours.
  • FIG. 1 shows a magnet rod in contact with a conical flask containing rat L6 cell culture medium. After 48 hours, the floor of the conical flask was photographed from one end to the other, and the cell count was calculated, with the results shown in FIG. 2 .
  • the part near the magnet shows the area of the magnet end surface at the floor of the conical flask, and the part at a distance from the magnet shows the region on the side opposite the magnet end surface at the floor of the conical flask.
  • FIG. 2 shows that, near the magnet, the iron-salen complexes were attracted, resulting in a greater iron-salen complex concentration, so that the DNA-growth inhibition action of the iron-salen complexes resulted in a dramatically lower number of cells than farther away.
  • a system equipped with magnetism-generating means and drugs rendered magnetic by the present invention can thus allow drugs to become concentrated in target tissues and affected sites of individuals.
  • a pair of magnets 230 and 232 facing each other in the direction of gravity are supported by a stand 234 and clamp 235 , and a metal plate 236 is located between the magnets.
  • the metal plate especially an iron plate, is placed between the pair of magnets to locally create a magnetic field of uniform strength.
  • An electrical magnet can be used instead of a magnet to modify the magnetic force generated in this delivery device.
  • the magnetism-generating means can be moved to a target position of the individual on a table to allow the pair of magnetism-generating means to move in the X, Y, and Z directions.
  • the tissue of an individual can be placed in the region of the magnetic field to concentrate the drug in the tissue.
  • Existing metal complexes drug concentration 5 mg/mL (15 mM)
  • mice weighing about 30 g were injected into mice weighing about 30 g, a laparotomy was performed, and the mouse was placed on the iron plate to allow the right kidney to move between the pair of magnets.
  • the magnets were Product No. N50 (neodymium permanent magnet) by Shin-Etsu Kagaku Kogyo, with a residual flux density of 1.39 to 1.44 T.
  • the magnetic field applied to the right kidney was about 0.3 (T)
  • the field applied to the left kidney was about 1/10.
  • a magnetic field was applied to the right kidney of the mouse, and after 10 minutes the SNR was measured by MRI in T1 mode and T2 mode.
  • FIG. 4 it was confirmed that the drug stayed in the right kidney (RT) to which the magnetic field was applied, as compared to the left kidney (LT) and control.
  • FIG. 5 shows the effect of the salen complexes on melanoma growth in mice.
  • Melanoma was established in mouse tails in vivo by local grafting of cultured melanoma cells (Clone M3 melanoma cells).
  • the salen complex (shown as SC, 50 mg/kg) was administered intravenously via tail vein, followed by local application of a magnetic field by the use of a commercially available bar magnet (630 mT, a cylindrical neodymium magnet, 150 mm in depth and 20 mm in diameter).
  • Application of a bar magnet was performed with 3 hour gentle touch to the site of melanoma immediately after injection of the salen complex for 10-14 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
US12/146,624 2007-12-28 2008-06-26 Iron-salen complex Abandoned US20090169484A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/990,981 US10034941B2 (en) 2007-12-28 2016-01-08 Iron-salen complex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007338928 2007-12-28
JP2007-338928 2007-12-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/990,981 Continuation US10034941B2 (en) 2007-12-28 2016-01-08 Iron-salen complex

Publications (1)

Publication Number Publication Date
US20090169484A1 true US20090169484A1 (en) 2009-07-02

Family

ID=40798707

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/146,624 Abandoned US20090169484A1 (en) 2007-12-28 2008-06-26 Iron-salen complex
US14/990,981 Active 2028-11-21 US10034941B2 (en) 2007-12-28 2016-01-08 Iron-salen complex

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/990,981 Active 2028-11-21 US10034941B2 (en) 2007-12-28 2016-01-08 Iron-salen complex

Country Status (2)

Country Link
US (2) US20090169484A1 (fr)
JP (3) JP4446489B2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239138A (zh) * 2008-11-20 2011-11-09 株式会社Ihi 自磁性金属salen络合物
US20130029399A1 (en) * 2010-04-06 2013-01-31 Yoshihiro Ishikawa Metal salen complex derivative and process for production thereof
CN102918118A (zh) * 2010-06-01 2013-02-06 株式会社Ihi 荧光色素材料及其使用方法
EP2564852A1 (fr) * 2010-04-28 2013-03-06 IHI Corporation Médicament traitant les tumeurs cérébrales
EP2657223A1 (fr) * 2010-12-21 2013-10-30 IHI Corporation Composé complexe métal-salen et son procédé de production
US8691261B2 (en) 2005-08-31 2014-04-08 Ihi Corporation Drug, drug guidance system, magnetic detection system, and drug design method
EP2738158A1 (fr) * 2011-06-13 2014-06-04 IHI Corporation Composé complexe métal salène, anesthésique local, et agent tumoral anti-malignité
CN103889947A (zh) * 2011-07-26 2014-06-25 株式会社Ihi 自磁性金属萨伦络合化合物
CN104010638A (zh) * 2011-10-06 2014-08-27 株式会社Ihi 磁性组合物及其制造方法
US20150336998A1 (en) * 2013-02-05 2015-11-26 Ihi Corporation Magnetic substance
US9314602B2 (en) 2009-12-25 2016-04-19 Ihi Corporation Magnetic body and drug delivery control device using magnetic body
EP3124114A4 (fr) * 2014-03-28 2017-11-29 Kyushu University, National University Corporation Réaction de transestérification effectuée au moyen d'un catalyseur à base de fer
US10030039B2 (en) 2014-09-26 2018-07-24 Ihi Corporation Anti-cancer agent and cancer cell killing method
US10034941B2 (en) 2007-12-28 2018-07-31 Ihi Corporation Iron-salen complex
CN109415304A (zh) * 2016-06-27 2019-03-01 株式会社可乐丽 铁络合物的制造方法和使用了铁络合物的酯化合物的制造方法
IT202000016255A1 (it) * 2020-07-06 2022-01-06 Eni Spa Nuovi complessi metallici con leganti tipo-salen.

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5077796B2 (ja) * 2008-03-10 2012-11-21 独立行政法人科学技術振興機構 Ｏ、ｓ又はｎを含む鎖状アルキル化合物の製造方法
JP2009289799A (ja) * 2008-05-27 2009-12-10 Yoshihiro Ishikawa スイッチング素子
JP2012176905A (ja) * 2011-02-25 2012-09-13 Ihi Corp 金属サレン錯体化合物
JP2012131737A (ja) * 2010-12-21 2012-07-12 Ihi Corp 金属サレン錯体化合物及びその製造方法
JP5829871B2 (ja) * 2011-09-16 2015-12-09 株式会社Ihi リポソーム薬剤
JP5806356B2 (ja) * 2014-03-10 2015-11-10 株式会社Ihi 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727068A (en) * 1985-10-23 1988-02-23 Johnson Matthey, Inc. Radiosensitization by cobalt and Fe(III) complexes
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US6162469A (en) * 1996-06-10 2000-12-19 Nittetsu Mining Co., Ltd. Medical powder
US6344516B1 (en) * 1999-06-29 2002-02-05 National Institute Of Advanced Industrial Science And Technology Resin composition and process for producing the same

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
NL7304882A (fr) 1972-04-10 1973-10-12
JPS62192383A (ja) 1986-02-20 1987-08-22 Hidetoshi Tsuchida ポリテトラアザポルフイン鉄錯体および有機磁性材料
DE3618840A1 (de) 1986-06-04 1987-12-10 Basf Ag Methanol/luft-brennstoffzellen
JP3000369B2 (ja) * 1989-05-16 2000-01-17 日本酸素株式会社 酸素吸収錯体の再生方法及び酸素吸収錯体溶液を用いた酸素の分離方法
JPH0523276A (ja) 1991-07-15 1993-02-02 Tokyo Electric Co Ltd 電気掃除機
JP2930263B2 (ja) 1991-08-12 1999-08-03 日本化薬株式会社 電子写真用トナー
JPH05216967A (ja) 1992-02-03 1993-08-27 Hitachi Ltd 分子設計支援装置
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US6200547B1 (en) 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
DE69429507T2 (de) 1993-01-29 2002-05-16 Ferx Inc Magnetisch reagierende zusammensetzung als träger für biologisch aktive substanzen und verfahren für ihre herstellung und verwendung
JPH07296045A (ja) 1994-04-27 1995-11-10 Hitachi Ltd 分子設計支援方法
KR100252743B1 (ko) 1994-12-29 2000-09-01 나가야마 오사무 Il-6 안타고니스트를 함유하는 항종양제의 작용증강제
JP3724051B2 (ja) 1996-04-25 2005-12-07 住友化学株式会社 フェノールの酸化重合用触媒およびフェノールの酸化重合法
JP3825501B2 (ja) 1996-06-10 2006-09-27 吉郎 岡見 微小物質保持担体、その懸濁系、微小物質操作装置及び微小物質位置制御方法
PT1007533E (pt) 1996-08-27 2005-09-30 Univ Utah Res Found Bioconjugados e administracao de agentes bioactivos
JPH10310796A (ja) 1997-05-14 1998-11-24 Lion Corp カビ取り剤組成物
JP3030849B2 (ja) 1997-06-18 2000-04-10 科学技術振興事業団 有機高分子化合物の強磁性を予測する方法
JPH11217385A (ja) 1998-01-30 1999-08-10 Nihon Schering Kk 含フッ素ポルフィリン錯体およびそれを含有する造影剤
JPH11279100A (ja) 1998-03-25 1999-10-12 Asahi Glass Co Ltd 光学活性な１−置換−２−プロパノールの製造方法
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
JP2000269013A (ja) 1999-03-12 2000-09-29 Kanagawa Acad Of Sci & Technol 分子性磁性体
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
JP4433118B2 (ja) 2000-09-12 2010-03-17 日産化学工業株式会社 分子磁性体およびその製造方法
JP2002226678A (ja) * 2000-11-28 2002-08-14 Sumitomo Bakelite Co Ltd 難燃性エポキシ樹脂組成物およびそれを用いた半導体封止材料並びに半導体装置
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
WO2002071054A1 (fr) 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatographie de complexes metalliques
GB0125357D0 (en) 2001-10-22 2001-12-12 Univ Brighton Improvements relating to catalytic antioxidants
WO2003086563A2 (fr) 2002-04-11 2003-10-23 Carbomer, Inc. Nouvelles sondes d'imagerie de diabete
JP4357847B2 (ja) 2003-02-04 2009-11-04 三菱電機株式会社 物質の磁気特性を予測する方法
GB0316912D0 (en) 2003-07-18 2003-08-20 Oxford Instr Superconductivity Therapeutic treatment
US7119065B2 (en) 2003-10-29 2006-10-10 Nagoya Industrial Science Research Institute Metal complex-protein composite and oxidation catalyst
JP2005154402A (ja) * 2003-10-29 2005-06-16 Nagoya Industrial Science Research Inst 金属錯体タンパク質複合体及び酸化触媒
JP4265387B2 (ja) 2003-11-26 2009-05-20 株式会社日立製作所 時刻誤差算出機能付きクライアントサーバシステム
WO2006133354A2 (fr) 2005-06-08 2006-12-14 University Of Kansas Procede de production de complexes de metaux nanoparticulaires et de modification de morphologie des nanoparticules
JP2007091710A (ja) 2005-08-31 2007-04-12 Ishikawajima Harima Heavy Ind Co Ltd 薬、薬の誘導装置、磁気検出装置及び薬の設計方法
EP2036550A4 (fr) 2006-06-28 2009-07-15 Ihi Corp Medicament,dispositif d'administration de medicament,detecteur magnetique et procede de conception de medicament
JP4774536B2 (ja) 2006-11-06 2011-09-14 株式会社Ｉｈｉ 磁性材料、磁性材料の誘導装置及び磁性材料の設計方法
JP5167481B2 (ja) 2006-11-07 2013-03-21 株式会社Ｉｈｉ 抗がん薬
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
WO2010058280A1 (fr) * 2008-11-20 2010-05-27 株式会社Ihi Composé complexe de métal-salène auto-magnétique
WO2011135784A1 (fr) * 2010-04-28 2011-11-03 株式会社Ihi Médicament traitant les tumeurs cérébrales
US9282923B2 (en) * 2010-06-01 2016-03-15 Ihi Corporation Fluorochrome material and method for using the same
EP2657223B1 (fr) * 2010-12-21 2017-06-28 IHI Corporation Composé complexe métal-salen et son procédé de production
JP6017766B2 (ja) * 2011-07-26 2016-11-02 株式会社Ihi 新規な金属サレン錯体化合物の抗がん剤
JP6046338B2 (ja) * 2011-10-27 2016-12-14 株式会社Ihi ラジカル抑制剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727068A (en) * 1985-10-23 1988-02-23 Johnson Matthey, Inc. Radiosensitization by cobalt and Fe(III) complexes
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US6162469A (en) * 1996-06-10 2000-12-19 Nittetsu Mining Co., Ltd. Medical powder
US6344516B1 (en) * 1999-06-29 2002-02-05 National Institute Of Advanced Industrial Science And Technology Resin composition and process for producing the same

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691261B2 (en) 2005-08-31 2014-04-08 Ihi Corporation Drug, drug guidance system, magnetic detection system, and drug design method
US10034941B2 (en) 2007-12-28 2018-07-31 Ihi Corporation Iron-salen complex
CN102239138A (zh) * 2008-11-20 2011-11-09 株式会社Ihi 自磁性金属salen络合物
CN104800195A (zh) * 2008-11-20 2015-07-29 株式会社Ihi 自磁性金属salen络合物
US9505732B2 (en) 2008-11-20 2016-11-29 Ihi Corporation Auto magnetic metal salen complex compound
US9314602B2 (en) 2009-12-25 2016-04-19 Ihi Corporation Magnetic body and drug delivery control device using magnetic body
US20130029399A1 (en) * 2010-04-06 2013-01-31 Yoshihiro Ishikawa Metal salen complex derivative and process for production thereof
RU2533567C2 (ru) * 2010-04-06 2014-11-20 АйЭйчАй КОРПОРЕЙШН Производные комплекса металл-сален и способ их получения
US9603940B2 (en) * 2010-04-06 2017-03-28 Ihi Corporation Metal salen complex derivative and process for production thereof
EP2564852A4 (fr) * 2010-04-28 2013-10-02 Ihi Corp Médicament traitant les tumeurs cérébrales
US20130131367A1 (en) * 2010-04-28 2013-05-23 Ihi Corporation Anti-brain-tumor drug
US8933118B2 (en) * 2010-04-28 2015-01-13 Ihi Corporation Anti-brain-tumor drug
EP2564852A1 (fr) * 2010-04-28 2013-03-06 IHI Corporation Médicament traitant les tumeurs cérébrales
RU2547570C2 (ru) * 2010-04-28 2015-04-10 АйЭйчАй КОРПОРЕЙШН Лекарственное средство против опухоли головного мозга
CN102918118A (zh) * 2010-06-01 2013-02-06 株式会社Ihi 荧光色素材料及其使用方法
US9282923B2 (en) 2010-06-01 2016-03-15 Ihi Corporation Fluorochrome material and method for using the same
CN103517895A (zh) * 2010-12-21 2014-01-15 株式会社Ihi 金属沙仑配位化合物及其制造方法
EP2657223A1 (fr) * 2010-12-21 2013-10-30 IHI Corporation Composé complexe métal-salen et son procédé de production
EP2944627A1 (fr) * 2010-12-21 2015-11-18 IHI Corporation Composés complexes métalliques de salen de taille nanométrique, leur préparation et leur usage comme agents anti-tumoraux systémiques.
EP2657223A4 (fr) * 2010-12-21 2014-12-24 Ihi Corp Composé complexe métal-salen et son procédé de production
RU2546663C2 (ru) * 2010-12-21 2015-04-10 АйЭйчАй КОРПОРЕЙШН Комплексное соединение металл-сален и способ его получения
US9005757B2 (en) 2010-12-21 2015-04-14 Ihi Corporation Metal-salen complex compound and method for producing the same
EP2738158A1 (fr) * 2011-06-13 2014-06-04 IHI Corporation Composé complexe métal salène, anesthésique local, et agent tumoral anti-malignité
EP2738158A4 (fr) * 2011-06-13 2014-12-17 Ihi Corp Composé complexe métal salène, anesthésique local, et agent tumoral anti-malignité
US10034851B2 (en) 2011-06-13 2018-07-31 Ihi Corporation Metal-salen complex compound, local anesthetic and antineoplastic drug
RU2649391C2 (ru) * 2011-07-26 2018-04-03 АйЭйчАй КОРПОРЕЙШН Комплексное металл-саленовое соединение, обладающее собственным магнетизмом
EP2738157A4 (fr) * 2011-07-26 2015-10-14 Ihi Corp Composé complexe métal-salen auto-magnétique
CN103889947A (zh) * 2011-07-26 2014-06-25 株式会社Ihi 自磁性金属萨伦络合化合物
US9592219B2 (en) 2011-07-26 2017-03-14 Ihi Corporation Self-magnetic metal-salen complex compound
RU2573400C1 (ru) * 2011-10-06 2016-01-20 АйЭйчАй КОРПОРЕЙШН Магнитная композиция и способ ее получения
EP2774611A4 (fr) * 2011-10-06 2015-03-04 Ihi Corp Composition magnétique et procédé de production associé
CN104010638A (zh) * 2011-10-06 2014-08-27 株式会社Ihi 磁性组合物及其制造方法
US9469668B2 (en) * 2013-02-05 2016-10-18 Ihi Corporation Magnetic substance
US20150336998A1 (en) * 2013-02-05 2015-11-26 Ihi Corporation Magnetic substance
EP3124114A4 (fr) * 2014-03-28 2017-11-29 Kyushu University, National University Corporation Réaction de transestérification effectuée au moyen d'un catalyseur à base de fer
US10030039B2 (en) 2014-09-26 2018-07-24 Ihi Corporation Anti-cancer agent and cancer cell killing method
CN109415304A (zh) * 2016-06-27 2019-03-01 株式会社可乐丽 铁络合物的制造方法和使用了铁络合物的酯化合物的制造方法
US10646859B2 (en) 2016-06-27 2020-05-12 Kuraray Co., Ltd. Method for producing iron complexes and method for producing ester compounds using iron complex
IT202000016255A1 (it) * 2020-07-06 2022-01-06 Eni Spa Nuovi complessi metallici con leganti tipo-salen.

Also Published As

Publication number Publication date
US10034941B2 (en) 2018-07-31
JP2010043125A (ja) 2010-02-25
US20160193337A1 (en) 2016-07-07
JP2014133743A (ja) 2014-07-24
JP2009173631A (ja) 2009-08-06
JP4446489B2 (ja) 2010-04-07
JP5997189B2 (ja) 2016-09-28
JP5461968B2 (ja) 2014-04-02

Similar Documents

Publication Publication Date Title
US10034941B2 (en) Iron-salen complex
US9505732B2 (en) Auto magnetic metal salen complex compound
JP2010043125A5 (fr)
He et al. Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer
Kumar et al. Image-guided breast tumor therapy using a small interfering RNA nanodrug
US20140046021A1 (en) Self-magnetic metal-salen complex compound
Patel et al. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates
Liu et al. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma
US10034851B2 (en) Metal-salen complex compound, local anesthetic and antineoplastic drug
Sang et al. A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer
Glass et al. Optimizing mannose “click” conjugation to polymeric nanoparticles for targeted siRNA delivery to human and murine macrophages
US9592219B2 (en) Self-magnetic metal-salen complex compound
JP6358661B2 (ja) 界面活性剤様化合物
JP2009196913A (ja) 磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
Xie et al. EGFR-targeted and gemcitabine-incorporated chemogene for combinatorial pancreatic cancer treatment
Song et al. Synthetic polymer material modified by d-peptide and its targeted application in the treatment of non-small cell lung cancer
Chen et al. Chemical Amplification-Enabled Topological Modification of Nucleic Acid Aptamers for Enhanced Cancer-Targeted Theranostics
JP2009256233A (ja) 磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
JP2009256232A (ja) 磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
Xu et al. Piperazine-derived ionizable lipids for enhanced mRNA delivery and cancer immunotherapy
CN113521296A (zh) EGFR适配子修饰负载miR-375及PTX的RNA纳米药物及制备方法和应用
CN113171469A (zh) 靶向肿瘤细胞表面Trop2蛋白的肿瘤治疗纳米药物及其制备方法
Zhou et al. PAMAM Dendrimer as Potential Delivery System for Combined Chemotherapeutic and MicroRNA-21 Gene Therapy
JP2013170133A (ja) 無機化合物、無機化合物を含む薬剤、薬剤の誘導システム、及び磁気検出装置、並びにがん温熱治療法装置
Trojahn et al. The Development of Targeted Nanoparticulate Contrast Agents for Magnetic Resonance Imaging of Brain Tumors.

Legal Events

Date Code Title Description
AS Assignment

Owner name: YOSHIHIRO ISHIKAWA, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EGUCHI, HARUKI;ISHIKAWA, YOSHIHIRO;REEL/FRAME:021537/0083

Effective date: 20080528

Owner name: IHI CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EGUCHI, HARUKI;ISHIKAWA, YOSHIHIRO;REEL/FRAME:021537/0083

Effective date: 20080528

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION